Development of small molecule inhibitors of MEIS proteins
The MEIS1 (myeloid ecotropic viral insertion site 1) gene was identified at one of the viral integration sites in myeloid leukaemic cells and has been associated with oncogenic transformation. Its product, MEIS1 protein, acts as a co-factor of homeodomain-containing transcription factors that are involved in the control of numerous processes during embryonic development. Latest research has demonstrated that MEIS proteins are associated with decreased cardiac regeneration, decreased stem cell proliferation and cancer progression. The EU-funded MEISi project supports efforts of the biotech start-up Meinox to develop small drug inhibitors of MEIS protein as a potential critical factor in the treatment of myocardial injuries, bone failure and cancer. Currently, Meinox aims to conduct a feasibility study and risk analysis and to develop a robust commercialisation plan.
Fields of science
Call for proposal
See other projects for this call